Literature DB >> 9448551

The effects of improved glycemic control on complications in type 2 diabetes.

B Gaster1, I B Hirsch.   

Abstract

Type 2 diabetes is 8 to 10 times more common than type 1 diabetes, but no single large trial has established that improved glycemic control can prevent complications in type 2 diabetes. We have reviewed the results of the existing epidemiologic and clinical trial studies and have arrived at the following conclusions: (1) Strong evidence exists that improved glycemic control is effective at lessening the risks of retinopathy, neuropathy, and nephropathy in type 2 diabetes. (2) The evidence about the effect on coronary heart disease is limited and equivocal. (3) The hypoglycemic risk from improved glycemic control is significantly less in type 2 diabetes than in type 1, and weight gain seems to be modest. In conclusion, although glycemic goals should be individualized based on several clinical factors, most patients with type 2 diabetes would probably benefit from glucose lowering to a hemoglobin A1c level between 7% and 8%.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448551     DOI: 10.1001/archinte.158.2.134

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  29 in total

1.  Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.

Authors:  Giovanni Corrao; Silvana Antonietta Romio; Antonella Zambon; Luca Merlino; Emanuele Bosi; Marina Scavini
Journal:  Eur J Clin Pharmacol       Date:  2010-11-19       Impact factor: 2.953

2.  Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction.

Authors:  C E Mogensen
Journal:  BMJ       Date:  1998-09-12

Review 3.  Screening for diabetes: what are we really doing?

Authors:  E Goyder; L Irwig
Journal:  BMJ       Date:  1998-12-12

4.  Treatment of diabetic sensory polyneuropathy.

Authors:  Lindsay Zilliox; James W Russell
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 5.  Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

Authors:  L J Scott; C M Spencer
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells.

Authors:  Xiao C Li; Oscar A Carretero; Jia L Zhuo
Journal:  Biochem Pharmacol       Date:  2006-03-28       Impact factor: 5.858

7.  GLP-1 receptor agonist on cardiovascular complications of diabetes mellitus.

Authors:  Fengjun Liu; Yanhua Kong
Journal:  Exp Ther Med       Date:  2020-01-20       Impact factor: 2.447

8.  Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.

Authors:  Jennifer Q Dong; Michelle Rossulek; Veena R Somayaji; Daniel Baltrukonis; Yali Liang; Krischan Hudson; Martha Hernandez-Illas; Roberto A Calle
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

9.  The Hispanic paradox and predictors of mortality in an aging biethnic cohort of Mexican Americans and European Americans: the san antonio longitudinal study of aging.

Authors:  Sara E Espinoza; Inkyung Jung; Helen Hazuda
Journal:  J Am Geriatr Soc       Date:  2013-09-03       Impact factor: 5.562

Review 10.  Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.

Authors:  S C L Gough; J Tibaldi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.